Next generation theranostic pair offers new strategy to detect and treat metastatic kidney cancer

A recently developed radiotheranostic pair, 68Ga/177Lu-NYM096, tin place tumors and efficaciously present targeted radiotherapy to patients with metastatic wide compartment renal compartment carcinoma (ccRCC). Using a small-molecule compound, the caller attack helps mitigate toxicity issues communal with treatment, offering a harmless and feasible strategy for those with end-stage disease. This probe was published successful the September contented of The Journal of Nuclear Medicine.